One of the aims of research in the area of thrombosis has been to design an effective anticoagulant that would function in a predictable and direct manner. In evaluating the role of coagulation in sepsis we used factor Xa blocked in the active center with [5-(dimethylamino)l-naphthalenesulfonyl]-glutamylglycylarginyl chloromethyl ketone (DEGR-Xa). We infused 1 mg/kg of DEGR-Xa together with LD,, concentrations of Escherichia coli (4 x 10" organismdkg) into five baboons. As controls, we infused E coli alone into five baboons. The inflammatory, coagulant, and cell injury responses to Ecoliof both the treated and control groups were lethal and were similar in every respect except for the HAVE PREVIOUSLY shown that infusion of w activated protein C' or antibodies to tissue factor2 into baboons before challenge with Escherichia coli protects the animals from the consumptive coagulopathy, organ damage, and lethal effects of the E coli. Because activated protein C is an anticoagulant, the question arose from these studies as to whether protection was due solely to the anticoagulant activity. To address this question, a specific, mechanism-based anticoagulant was required.
tional proteins in the bone, probably leading to birth defects in some infants born to mothers treated with oral anticoagulants, especially during the first trimester of pregnancy."' Finally, warfarin inhibits synthesis of proteins C and S, two components of a critical anticoagulant pathway." This action may contribute to the rare but serious complication of oral anticoagulant therapy commonly referred to as warfarin-induced skin necrosis.'' These complications have led many investigators to seek alternative anticoagulants. In this quest, investigators have explored the possibility of using low molecular weight protease inhibitors such as the chloromethyl ketonesI3 or naturally occurring inhibitory proteins such as hirudin from leaches.I4 Although both appear to be effective," their specificity and potential side effects remain to be determined.
To evaluate further the role of coagulation in sepsis, we attempted to design another inhibitor that would specifically block coagulation. A model for such an inhibitor was suggested from an analysis of the reactions involved in coagulation. Each of these reactions has the common feature of the coagulation protease forming a complex with the activated regulatory protein (cofactor). In the case of the prothrombin activation complex, this corresponds to a membrane-bound complex of activated factor V (Va, cofactor) and activated factor X (Xa, protease).I6 Binding of factor Xa to Va on the membrane surface is independent of the active site. Thus, factor Xa blocked in the active center with low molecular weight inhibitors can compete with active factor Xa for binding to factor Va.I6 In vivo this binding of factor Xa is further controlled by a limited number of high-affinity binding sites on the surface of cells." Thus, active-site blocked coagulation factors could serve as potential anticoagulants."
In this report we demonstrate that, although factor Xa blocked in the active center with Dansyl Glu Gly Arg chloromethyl ketone (DEGR-Xa) can inhibit disseminated intravascular coagulation (DIC) induced by infusion of E coli, this inhibitor fails to block the lethal effects of the bacterial infusion.
MATERIALS AND METHODS

Preparation of proteins.
Bovine factor X was isolated and activated with the purified factor X activator from Russell's Viper venom as described previo~sly.'~ The venom activator was then 
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separated from the factor Xa by chromatography on a QAE Sephadex column. Under the conditions used, the activator does not bind to the column and the factor Xa is eluted with a linear NaCl gradient at approximately 0.5 molL NaCl. DEGR-Xa was formed by incubating factor Xa (0.94 mg/mL, in 18 mL of 0.1 molL NaCI, 0.5 molL MOPS, pH 7.5) with 1.2 mL of DEGR (1 mg/mL in 1 mmoVL HC1) for 30 minutes at room temperature before exhaustive dialysis against 0.1 molL NaC1, 1 mmol/L Tris-HC1 pH 7.5.*' Although less than 0.1% of the original factor Xa activity could be detected with the chromogenic activity, the sample was routinely treated with bovine antithrombin I11 (50 pg/mL) to remove any residual factor Xa activity. The inhibitor activity of this DEGR-Xa preparation was assayed using the thromboplastin clotting assay. Figure 1 shows that as little as 1 pg/mL of DEGR-Xa in the assay prolonged the clotting time from 25 to 54 seconds.
Experiments were performed on 10 juvenile baboons, (Pupw c. cynocephalus), each with a hematocrit exceeding 36% and free from tuberculosis. Baboons were fasted overnight before each experiment and given water ad libitum. Each animal was sedated with ketamine hydrochloride (14 mg/kg, intramuscular [IM]) on the morning of the study, and anesthetized with sodium pentobarbital (2 mgkg) via a percutaneous catheter positioned in the cephalic vein. The femoral artery and both femoral veins were cannulated aseptically and used for measuring aortic pressure, obtaining blood samples, infusing live organisms, DEGR-Xa, and for fluid and anesthetic administration as previously described.' Each baboon was placed on its side in contact with controlled temperature heating pads and rectal temperature was monitored as previously reported.' Animals were intubated orally, allowed to breathe spontaneously, and respiration rates were recorded. A light level of surgical anesthesia was maintained for the 6-hour observation period (2 mgkg sodium pentobarbital approximately every 20 to 45 minutes).
Infusion studies. T -0 designated the point at which the infusion of E coli was started. Not more than 10% of the baboon's estimated total blood volume (70 mL/kg) was withdrawn over the 6-hour monitoring period. The blood sampled at each drawing included: 1 mL anticoagulated with enthylenediaminotetraacetic acid for complete blood count (CBC), hematocrit, platelet and differential counts; 2.0 mL anticoagulated with 3.8% sodium citrate for fibrinogen? factor V,= and tumor necrosis factor (TNF) using the L929 cytotoxicity a s s a y ; 1.0 mL in trasylolithrombin for fibrin degradation products (FDP)"; 1.0 mL of clotted blood for blood urea nitrogen (BUN)x and creatinine (CR)"; 1.0 mL of whole blood at T -0, T + 120, and T + 360 minutes for colony counts.28
Clearance of the DEGR-Xa from the circulation was studied by two methods. In the first method, the protein was radioiodinated using Enzymobeads (BioRad, Richmond, CA) according to the manufacturer's instructions. After desalting and dialysis, '*'I DEGR-Xa (0.79 mg/mL, 5.7 mL, 20,000 cpm/mL) was infused into the baboon 60 minutes before the E coli infusion. Fractions of 0.5 mL whole blood were collected at T -60, 0, +60, +120, + B O , +240, +360 minutes, and at 24 hours and counted in a gamma counter (Nuclear Enterprises, NE 1600; San Carlos, CA). In the second method, the clearance of bovine DEGR-Xa from the circulation was monitored with an enzyme-linked immunosorbent assay (ELISA) that used a monoclonal antibody (MoAb) (cell line #551B4-1) to bovine factor X that recognized bovine DEGR-Xa but not baboon or human factor X or Xa. A brief summary of the steps in the ELISA are: (1) adsorb goat antimouse IgG (5 pg/mL) to the assay plate for 16 hours at 4"C, block excess sites, and wash; (2) react a 1/32 dilution of a hybridoma supernatant to bovine factor X with the coated plate and wash; (3) add either baboon plasma supplemented in vitro with DEGR-Xa or plasma samples from experimental animals supplemented with DEGR-Xa in vivo and wash; (4) detect bovine DEGR-Xa with affinity-purified, biotin-labeled goat anti-factor X antibody (5 pg/mL), wash, add streptavidin-alkaline phosphatase conjugate, wash, and add the substrate. Washes were performed three times with 0.15 molL NaCl, 0.02 m o m Tris-HCI, 10 mg/mL bovine serum albumin (BSA) at pH 7.5. The reactions in steps two through four were performed for 1 hour at 37°C. The substrate in step four was p-nitrophenylphosphate (1 mg/mL), in 0.18 m o m carbonate, 2 m m o w MgC12, 0.02% NaN,, pH 8.6. The plate was incubated in the dark for 1 hour at 22°C and the A405 determined as with a vMax plate reader and analyzed with the SOFTmax program from Molecular Devices. The sensitivity of the assay was 50 ng/mL.
Data were analyzed using the Student's t-test to determine significant differences (P < .05) in means between groups at given times ( Table 1 ). The analysis of variance and the multicomparison Duncan's test were used to determine significant differences between means at time 0 and subsequent times within groups (Fig  2) .
RESULTS
Two groups of animals (control and treated) were used. Table 2 shows the conditions, number of organisms infused and found circulating in the blood at T + 2 hours, and survival times of animals in the two groups. In the control group (Fig 2, top) , infusion of LD,, E coli resulted in a decrease in MSAP and fibrinogen, and in the appearance of TNF in plasma comparable with that seen in other studies.',' Pretreatment with DEGR-Xa before infusion of E coli (Fig 2, bottom) , blocked fibrinogen consumption, but the decrease in blood pressure was comparable with the untreated control. As shown in Fig 2 (bottom) , DEGR-Xa was cleared from the circulation slowly. Thus, despite successfully blocking fibrinogen consumption and prolonging survival for a matter of hours, DEGR-Xa did not prevent the decrease in blood pressure, the elaboration of TNF (Fig 2, bottom) , the organ damage, or ultimate lethal effects of the bacterial infusion. Factor V consumption also was inhibited to the same extent as that found for fibrinogen.
As noted above, the DEGR-Xa was infused 1 hour before the bacterial challenge. Most proteases are cleared readily from the circulationz9 but the inhibitor influence of DEGR-Xa remained after 1 hour. This result implies that blocking the active center of factor Xa increased its half-life. When the clearance of the 'zI-labeled DEGR-Xa was measured, the half-life was approximately 10 hours (Fig  2, bottom) . When the clearance of DEGR-Xa was measured by ELISA, the half-life was approximately 2 hours (Fig 2, bottom) . This assay took advantage of the fact that the DEGR-Xa infused was isolated from bovine plasma and the MoAb to bovine Xa did not crossreact with baboon factor X.
No abnormal bleeding at operative sites was encountered. DEGR-Xa had no effect on the other parameters of the host response to E coli. These parameters include the sympathomimeticiinflammatory, coagulantifibrinolytic, and cell injury responses shown in Table 1 .
Postmortem examinations were conducted in all baboons. Tissues were removed within minutes after death, thereby avoiding postmortem autolytic changes. The tissues were removed and analyzed histologically for comparison of results between treated and untreated groups. The pathology was similar between these groups. However, there was decreased evidence of hemorrhage and thrombosis in the treated groups. There was alveolar capillary congestion, edema, and aggregation of neutrophils in the lungs. There was severe vascular congestion and accumulation of neutrophils in the vascular spaces of the liver. There was severe cortical congestion, hemorrhage, necrosis, and neutrophil accumulation in the adrenal glands. There was cortical necrosis, vascular congestion, and some hemorrhage in the kidneys. There was lymphoid follicular necrosis and medullary congestion in the spleen.
Relative to untreated control animals, infusion of DEGR-Xa alone at the same concentrations used in the above study produced no abnormal inflammatory, coagulopathic, or cardiovascular changes as reflected by the parameters measured in this study (not shown). Thus, the DEGRXa, while functioning effectively to inhibit the consumptive coagulopathic response to LD,, E coli, did not protect the animals from lethal shock.
DISCUSSION
At least two conclusions can be drawn from these studies. The first conclusion is that the mechanism of protection by activated protein C cannot be only via prevention of fibrin formation. The application of DEGR-Xa to the investigation of the process of gram-negative septic shock has allowed us for the first time to demonstrate clearly that, although coagulation occurs in gram-negative sepsis, fibrin formation per se is of limited importance in determining the lethality of E coli in this primate model. Thus, while there is a significant difference in the number of animals surviving less than 15 hours in the control group versus those surviving more than 15 hours in the experimental (DEGR-Xa) group (P = .02), we do not consider this difference to be of qualitative importance because (1) the decrease in blood pressure and elaboration of TNF were unaffected by treatment with DEGR-Xa, (2) the gross and microscopic pathologic findings were the same in both groups, and (3) death is used as the definitive endpoint in considering the significance of treatment in studies in which primates were used. The second conclusion is that a new generation of highly specific and extremely effective anticoagulants can be designed based on the well-established observations that activated coagulation zymogens (factors Xa and IXa) interact with their respective activated cofactors (factors Va and VIIIa) in an active-site-independent fashion.I6 The selectivity of the interaction for the activated forms of the coagulation zymogens and cofactors is undoubtedly why the very low levels of DEGR-Xa are effective as anticoagulants in vitro (Fig 1) and in vivo (Fig 2) .
The fact that the half-life of infused DEGR-Xa is hours instead of seconds, and the fact that plasma concentrations at 6 hours of 0.8 to 1.0 kg/mL completely inhibit fibrinogen consumption is of particular interest. These results are surprising because it has been shown that as much as 9 pg of active-site inhibited factor Xa is bound per lo5 bovine aortic endothelial cells.*' These studies suggest that the half-life of 1 mgikg of DEGR-Xa infused in vivo should be very short. However, determination of DEGR-Xa concentration by both radioisotopic and ELISA assays show that it is cleared slowly over a period of hours. The iodinated protein appeared to be cleared more slowly than the unlabeled protein, indicating that iodination may retard clearance. One explanation for this apparent discrepancy between the results of in vitro and in vivo studies is that the binding of active-site inhibited factor Xa in culture is increased through an increase in binding surface by vesiculation in the environment of the culture wells. In support of the in vitro vesiculation hypothesis, approximately one-half of the human endothelial cell prothrombinase activity was associated with the cell-free media and characterized as microparticle~.'~ Coupled with the low capacity of the endothelium for DEGR-Xa observed in this study, these observations suggest that much of the endothelial cell factor Xa binding activity and prothrombinase activity observed in vitro may be an adaptation of the cells to culture conditions. The in vivo clearance data illustrates the importance of combining in vivo with in vitro observations.
Another question of particular interest raised by these studies is why does one anticoagulant such as activated protein C protect, while another such as DEGR-Xa fails to protect? Because both agents are effective as anticoagulants, the difference in response suggests one of the following possibilities: (1) that activated protein C blocks a critical early step in coagulation that contributes to organ damage; (2) that activated protein C blocks one or more components of the inflammatory response; or (3) that activated protein C generates as yet unknown substances that inhibit elaboration of the inflammatory response and subsequent organ damage. For personal use only. on August 14, 2017 . by guest www.bloodjournal.org From
